PsychedelicNewsBreaks

MondayMay 24, 2021 11:52 am

PsychedelicNewsBreaks – Enveric Biosciences (NASDAQ: ENVB) Enters Strategic Agreement to Acquire MagicMed Industries

Enveric Biosciences (NASDAQ: ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced its entry into a definitive agreement to acquire MagicMed Industries Inc. in an all-stock transaction. MagicMed is a privately held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (“DMT”) and other molecular derivatives with applications across multiple indications. “Our proposed acquisition of MagicMed underscores the core fundamental mission of Enveric to form a drug discovery and clinical stage biotechnology company with a focus on bringing forward nature-originated therapies to improve the…

Continue Reading

ThursdayMay 20, 2021 12:25 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Strengthens IP Portfolio with 12th Patent Filing

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a provisional patent application in support of its ongoing drug candidate programs. The patent is the 12th patent filed by the company. In the announcement, the company noted that the application discloses novel compositions anticipated to have improved pharmacokinetic profiles while retaining significant efficacy measures of the original molecules; the patent also discusses innovative methods of deploying the novel compositions with faster therapeutic onset of Cybin’s psychedelic tryptamine, while reducing psychedelic side effects and decreasing duration of the therapeutic effect thereof. In addition, the patent…

Continue Reading

ThursdayMay 20, 2021 12:16 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leverages Key Initiatives to Advance Drug Candidates

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs. “Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (‘PFN’(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas,” reads a recent article regarding Tryp’s positioning. The piece also discusses the company’s three strategic initiatives. “Develop” is its first initiative, under which Tryp intends to utilize FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.…

Continue Reading

WednesdayMay 19, 2021 2:20 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Poised to Meet Demands of ‘Cannabis 2.0’

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is positioned in a market that is still relatively scant for certified extractors able to meet demand for concentrates from cannabis biomass. Having just achieved a milestone moment with commencement of production of 25,000 vape cartridges for the Canadian retail market, the company is set for opportunity amid “Cannabis 2.0,” a post-legalization era in Canada that has seen new consumption trends with accessibility of goods like drinks and vape products. “Demand for Pure Extracts’ Pure Pulls branded 510 Vape cartridges is strong in the provincial markets in Canada,” reads a recent…

Continue Reading

TuesdayMay 18, 2021 1:15 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Secures IRB Approval to Commence Study of Psilocybin Formulation in Treatment of Major Depressive Disorder

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the Institutional Review Board ("IRB") at the University of the West Indies Hospital in Jamaica has granted approval to commence the study of its sublingual psilocybin formulation ("CYB001") in a Phase II clinical trial for patients suffering with major depressive disorder ("MDD"). Commencement of the trial is subject to final confirmation of study material specifications by Jamaica’s Ministry of Health. "IRB approval for our study protocols is an important step forward to begin testing our proprietary psilocybin formulation delivered via absorption under the tongue…

Continue Reading

FridayMay 14, 2021 1:34 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner will distribute, store and deliver Covid-ID Lab test kits to XPhyto’s customers in line with product specifications and relevant logistical and regulatory requirements in Germany. A recent article quotes XPhyto CEO and Director Hugh Rogers, who noted that the company had secured a strong partner…

Continue Reading

FridayMay 14, 2021 9:56 am

PsychedelicNewsBreaks – WWC Conference Celebrates Women in Cannabis, Psychedelic Industries

The second-annual Womxn, Wellness and Cannabis Conference (“WWC Conference”) is expected to be the largest virtual event for women in the cannabis and psychedelic industries. Slated for May 26–27, the two-day event is hosted by Marigold PR in association with Lift & Co. Expo, a platinum partner and North America’s largest cannabis industry conference and tradeshow. The largest free event of its kind, the conference unites women globally for two days and features women-led panel discussions, Q&As and keynote speakers. The first day of the conference will focus on cannabis; the second day will focus on psychedelics. The conference agenda…

Continue Reading

FridayMay 14, 2021 9:38 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was featured in a recent “Forbes” article touting six keys to leadership growth. In the article, McKee shared valuable insight into the most effective ways that leaders can grow and develop. The behaviors McKee encouraged include staying curious and stepping outside of your comfort zone as well as not waiting for experiences and making experiences as you go. McKee also urged potential leaders to never stop learning and, in fact, noted that they could learn from every experience. McKee also encouraged leaders to not be afraid of breaking with convention.…

Continue Reading

ThursdayMay 13, 2021 11:53 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Collaborates to Potentially Develop New Therapy for Treatment-Resistant Psychiatric Disorders

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently acquired Adelia Therapeutics, thereby adding CYB003 to its pipeline. It subsequently made an equally important move when it inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to a recent article, “The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially develop a novel, fast-acting therapy for treatment-resistant psychiatric…

Continue Reading

WednesdayMay 12, 2021 11:47 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Opens Functional Mushroom Direct-to-Consumer Store on Amazon

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has opened an online, direct-to-consumer, e-commerce store through its wholly owned subsidiary, Pure Mushrooms Corp. The store, which will sell Pure Mushrooms Reishi and Maitake product formulations, is on the Amazon platform. Pure Mushroom Reishi and Maitake formulations are available in convenient, gluten-free capsules; the company anticipates releasing  a Lion’s Man formulation this summer. “We are excited to be on Amazon, the largest online marketplace and the most powerful platform in the world for brand…

Continue Reading